Rationale of the methodological approach to the creation of combined drugs

A. S. Nemchenko, Yu. I. Gubin, K. N. Toraev, L. V. Ievsieieva

Abstract


Efficient development of new drugs is only possible with a reasonable design research, because it requires integrating and coordinating the efforts of specialists in different fields. Currently there is a huge package of documents, and manuals in the field of registration and production of medicines (drugs). However, there are no generally accepted scientific guidelines about primary research at the pharmaceutical development of combination drugs. Our proposed methodological approach to the primary (basic) investigations and developed on the basis of his scheme (algorithm) of design combination drugs with the well-known active pharmaceutical ingredients (APIs) allows to Optimize research and reduce the risk of a negative result at the final stages of development of the drug.

Aim. To develop model for the initial design fixed-dose combination with known API and develop methodological approach to the creation of combined drugs.

Results. The general scheme (algorithm) was developed for combined drugs based on the combination of well-known API.

Conclusions. Offered methodological approach to designing a fixed combination of active substances, as part of the process of creating combined medicines.


Keywords


methodological approach; combination drugs; the creation of the medicines; drug design; algorithm

References


Настанова 42-4.3:2011. – Лікарські засоби. Фармацевтична система якості (ICH Q10) / М. Ляпунов, О. Безугла, О. Соловйов та ін. – К.: МОЗ України, 2011. – 22 с.

Настанова СТ-НМОЗУ 42-3.0:2011. – Лікарські засоби. Фармацевтична розробка (ICH Q8) / М. Ляпунов, О. Безугла, Ю. Підпружников та ін. – К.: МОЗ України, 2011. – 33 с.

Подпружников, Ю. В. Хрестоматия фармацевтического качества / Ю. В. Подпружников, А. А. Ишмухаметов, А. С. Немченко и др. – М.: ООО «Группа Ремедиум», 2015. – 432 с.

Challenge and Opportunity on the Critical Path to New Medical Products, FDA, Mach 2004.– Р. 31.

EMEA/CHMP/SWP/258498/2005 Guideline on the non-clinical development of fixed combinations of Medicinal products, London: EMEA, 2005. – Р. 5.

Drug Design & Manufacturing using Product Life cycle Management – HCL Technologies, 2011. – Р. 18.

Taking a Commercial Approach To Drug Development: Business, News & Politics. [Электронный ресурс]. – Режим доступу: http://www.slideshare.net/tmarten/taking-a-commercial-approach-to-drug-development

Yun, Bai. Strategies to Mitigate Technology Transfer and Clinical Manufacturing Risks: Downstream Purification Case Studies: [Электронный ресурс] / Yun Bai. – BioProcess International, 2014. – Режим доступу: http://www.bioprocessintl.com/business/risk-management/strategies-to-mitigate-technology-transfer-and-clinical-manufacturing-risks/


GOST Style Citations


1. Liapunov, M., Bezuhla, O., Soloviov, O. et al. (2011). Likarski zasoby. Farmatsevtychna systema yakosti (ICH Q10) [Medicines. Pharmaceutical Quality System (ICH Q10)]. ST-N MOZU 42-4.3:2011. Kyiv, 22.

2. Liapunov, M., Bezuhla, O., Pidpruzhnykov, Yu. et al. (2011). Likarski zasoby. Farmacevtychna rozrobka (ICH Q8) [Pharmaceutical development (ICH Q8)]. ST-N MOZU 42-3.0:2011. Kyiv, 33.

3. Podpruzhnikov, Yu. V., Ishmukhametov, A. A., Nemchenko, A. S., Andriukova, L. N., Yemshanova, S. V., Kozelskaia, T. C. et al. (2015). Khrestomatyia farmatsevtycheskoho kachestva [Chrestomathy pharmaceutical quality]. Moscow: Group Remedyum, 432.

4. Challenge and Opportunity on the Critical Path to New Medical Products. (2004). FDA, 31.

5. EMEA/CHMP/SWP/258498/2005 Guideline on the non-clinical development of fixed combinations of Medicinal products. (2005). London: EMEA, 5.

6. Drug Design & Manufacturing using Product Life cycle Management (2011).  HCL Technologies, 18.

7. Taking a Commercial Approach To Drug Development: Business, News & Politics. Available at: http://www.slideshare.net/tmarten/taking-a-commercial-approach-to-drug-development

8. Yun, Bai. (2014). Strategies to Mitigate Technology Transfer and Clinical Manufacturing Risks: Downstream Purification Case Studies. Available at: http://www.bioprocessintl.com/business/risk-management/strategies-to-mitigate-technology-transfer-and-clinical-manufacturing-risks/





DOI: https://doi.org/10.24959/uekj.17.4

Abbreviated key title: Upr. ekon. zabezp. âkostì farm.

ISSN 2519-8807 (Online), ISSN 2311-1127 (Print)